N-arylrolipram derivatives as potent and selective PDE4 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 22, 1998, Pages 3229-3234

  Bacher, Edmond ^a   Boer, Christiene ^a   Bray French, Katharine ^a   Demnitz, F W Joachim ^a,b   Keller, Thomas H ^a   Mazzoni, Lazzaro ^a   Müller, Thomas ^a   Walker, Christoph ^a  

^a Novartis Institutes for BioMedical Research   (United Kingdom)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 2 OXO PYRROLIDIN 1 YL] 5 (3 METHOXYBENZYLOXY)BENZOIC ACID N',N' DIMETHYLHYDRAZIDE; ANTIASTHMATIC AGENT; CYCLIC AMP; CYTOKINE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; ROLIPRAM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; EOSINOPHILIA; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; MONONUCLEAR CELL; NONHUMAN; RAT; REACTION ANALYSIS; SECOND MESSENGER; T LYMPHOCYTE;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0032541992     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00583-6     Document Type: Article

References (26)

1. 2. Phosphodiesterase Inhibitors: Schudt C., Dent G., Rabe K.F., Eds.; Academic Press: London, 1996.
2. 3. Torphy, T.J.; Cieslinski, L.B. Mol. Pharmacol. 1990, 37, 206.
3. 4. Hughes, G; Howat, D; Lisle, H.; Holbrook, M.; James, T.; Gozzard, K.; Blease, K.; Hughes, P.; Kingaby, R.; Warrellow, G.; Alexander R.; Head, J.; Boyd, E.; Eaton, M.; Perry, M.; Wales, M.; Smith, B.;Owens, R.; Catterall, C.; Lumb, S.; Russell, A.; Allen, R.; Merriman, M.; Blowham, D.; Higgs, G Br. J. Pharmacol. 1996, 118, 1183-1191.
4. 5. Raeburn, D.; Underwood, S.L.; Lewis, S.A.; Woodman, W.R.; Battram, C.H.; Tomkinson, A.; Sharma, S.; Jordan, R.; Souness, J.E.; Webber S.E.; Karlsson J. Br. J. Pharmacol. 1994, 113, 1423-1431.
5. 6. Stafford J.A.; Valvano, N.L.; Feldman, P.L.; Sloan Brawley, E.; Cowan, D.J.; Domanico, P.L.; Leesnitzer, M.A.; Rose D.A.; Simpson, S.A.; Strickland, A.B.; Unwalla, R.J.; Verghese, M.W. Bioorganic & Med. Chem. Lett. 1995, 5, 1977-1982.
6. 7. Masamune, H.; Cheng, J.B.; Cooper, K.; Eggler, J.F.; Marfat, A.; Marshall S.C.; Shirley, J.T.; Tickner, J. E.; Umland, J.P.; Vazquez, E. Bioorganic & Med. Chem. Lett. 1995, 5, 1965-1968.
7. 8. Kleinman, E.F.; Campbell, E.; Giordano, L.A.; Cohan, V.L.; Jenkinson, T.H.; Cheng, J.B.; Shirley, J.T.; Pettipher, E.R.; Salter, E.D.; Hibbs, T.A.; DiCapua, F.M.; Bordner, J. J. Med. Chem. 1998, 41, 266-270.
8. 9. Barnette, M.S.; Christensen, S.B.; Underwood, D.C.; Torphy, T.J. Pharmacol. Rev. Comm. 1996, 8, 65-73.
9. 10. Yamamoto, Y.; Kurate, I. Can. J. Chem. 1983, 61, 86.
10. 11. Müller, T; Engels, P.; Fozard, J.R. Trends Pharmacol. Sci. 1996, 17, 295-298.
11. 12. Compound 2 could only be dissolved in DMSO and attempts to dilute the solution with buffer lead invariably to precipitation.
12. 13. Counsell, R.E.; Smith, T.D.; Ranade, V.V.; Noronha, O.P.D.; Desai, P. J. Med. Chem. 1973, 16, 684-687.
13. 3 solution and then diluted with buffer as required. 2 mg 4 could be dissolved in 0.2 mL of ethanol and then diluted as required with buffer.
14. 27 expressed in S. cerevisae.
15. 16. Schneider, H.H.; Schmeichen, R.; Brezinski, M.; Siedler, J. Eur. J. Pharmacol. 1986, 127, 105-115.
16. 17. Rocque, W.J.; Tian G.; Wiseman, J.S.; Holmes, W.D.; Zajac-Thompson, I.; Willard, D.H.; Patel, I.R.; Wisely, G.B.; Clay, W.C.; Kadwell, S.H.; Hoffman, C.R.; Luther, M.A. Biochemistry, 1997, 36, 14250-14261.
17. 18. Christensen, S.B.; Guider, A.; Forster, C.J.; Gleason, J.G.; Bender, P.E.; Karpinski, J.M.; DeWolf, W.E. Jr.; Barnette, M.S.; Underwood, D.C.; Griswold, D.E.; Cieslinski, L.B.; Burman, M.; Bochnowicz, S.; Osborne, R.R.; Manning, C.D.; Grous, M.; Hillegas, L.M.; Bartus, O'Leary, J.; Ryan, M. D.; Eggleston, D.S.; Haltiwanger, R.C.; Torphy, T.J. J. Med. Chem. 1998, 41, 821.
18. 19. Romagnani, S. Curr. Opin. Immunol. 1994, 6, 838.
19. γ were purchased from Mabtech, Stockholm, Sweden. The sensitivity of the cytokine ELISAs was around 10 pg/mL.
20. 2. Concentration of TNFα in these supernatants was measured by sandwich ELISA using two monoclonal antibodies recognizing different epitopes of the specific cytokine (mAb357/101-4 and biotinylated 2-179/E11).
21. 22. Barnette, M.S.; Manning, C.D.; Cielinski L.B.; Burman, M.; Christensen, B.; Torphy, T.J. J. Pharmacol. Exp. Ther. 1995, 273, 674.
22. 23. Schneider, T.; van Velzen, D.; Moqbel, R.; Issekutz, A.C. Am. J. Respir. Cell Mol. Biol. 1997, 17, 702.1
23. 24. Engels, P.; Sullivan, M.; Müller, T.; Lübbert, H. FEBS Lett. 1995, 358, 305.
24. 25. Colicelli, J.; Birchmeier, C.; Michael, T.; O'Neill, K.; Riggs, M.; Wigler, M. Proc Natl Acad Sci USA 1989, 86, 3599-3903.
25. 26. Sullivan, M.; Egerton, M.; Shakur, Y.; Marquardsen, A.; Houslay M.D. Cell Signal. 1994, 6, 793-812.
26. 27. Baecker, P.A.; Obernolte, R.; Bach, C.; Yee, C.; Shelton, E.R. Gene 1994,138, 253-256.